Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 in Locally Advanced or Metastatic Solid Tumor
NCT05194982Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of izalontamab brengitecan in solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05194982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194982.